Neurocrine Biosciences, Inc. Live Share Price Today, Share Analysis and Chart

Name: Neurocrine Biosciences, Inc.: Is Infosys Ltd. worth buying?
Item: Neurocrine Biosciences, Inc.
Rating: 1.997888875
Author: Trendlyne DVM scores

Mid-range Performer

about

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

129.11 -0.29 (-0.22%)

53.28% Gain from 52W Low

387.4K

XNAS Volume

XNAS 03 Jul, 2025 5:30 PM (EDT)

Medium Financial Strength

38.9 / 100

Mid Valuation

33.8 / 100

Technically Neutral

48.2 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

160

1Yr Price target upside is 24%

25 analysts

Neurocrine Biosciences, Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neurocrine Biosciences, Inc. Live Share Price Today, Share Analysis and Chart

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

53.28% Gain from 52W Low

SWOT Analysis

Neurocrine Biosciences, Inc. Live Price Chart